Skip to main content

Table 2 .Demographics of subgroup study participants

From: Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer

Demographic characteristic

Group 1

Group 2

Group 3

UX first-line therapy

(n = 11)

Eri first-line therapy

(n = 12)

P-value

UX second-line or above therapy (n = 32)

Eri second-line or above therapy (n = 30)

P-value

Eri first-line therapy

(n = 12)

Eri second-line or above therapy (n = 30)

P-value

Age (year), %

         

 ≤ 50

6 (54.55%)

6 (50%)

 > 0.999

17 (53.13%)

13 (43.33%)

0.441

6 (50%)

13 (43.33%)

0.695

 > 50

5 (45.45%)

6 (50%)

 

15 (46.87%)

17 (56.67%)

 

6 (50%)

17 (56.67%)

 

Menopause, %

         

 Yes

5 (45.45%)

6 (50%)

 > 0.999

18 (56.25%)

17 (56.67%)

0.974

6 (50%)

17 (56.67%)

0.695

 No

6 (54.55%)

6 (50%)

 

14 (43.75%)

13 (43.33%)

 

6 (50%)

13 (43.33%)

 

BMI (kg/m2),%

         

 ≤ 22

6(54.55%)

6 (50%)

 > 0.999

19 (59.38%)

10 (33.33%)

0.04

6 (50%)

10 (33.33%)

0.483

 > 22

5(45.45%)

6 (50%)

 

13 (40.62%)

20 (66.67%)

 

6 (50%)

20 (66.67%)

 

T, %

         

 ≤ 2

1 (9.09%)

2 (16.67%)

 > 0.999

7 (21.87%)

3 (10.0%)

0.304

2 (16.67%)

3 (10.0%)

0.613

 > 2

10 (90.91%)

10 (83.33%)

 

25 (78.13%)

27 (90.0%)

 

10 (83.33%)

27 (90.0%)

 

N, %

         

 Yes

6 (54.55%)

11 (91.67%)

0.069

19 (59.38%)

25 (83.33%)

0.038

11 (91.67%)

25 (83.33%)

0.486

 No

5 (45.45%)

1 (8.33%)

 

13 (40.62%)

5 (16.67%)

 

1 (8.33%)

5 (16.67%)

 

M, %

         

 Yes

7 (63.64%)

1 (8.33%)

0.009

21 (65.62%)

7 (23.33%)

0.001

1 (8.33%)

7 (23.33%)

0.402

 No

4 (36.36%)

11 (91.67%)

 

11 (34.38%)

23 (76.67%)

 

11 (91.67%)

23 (76.67%)

 

ER, %

         

 + 

6(54.55%)

7 (58.33%)

 > 0.999

14 (43.75%)

13 (43.33%)

0.974

7 (58.33%)

13 (43.33%)

0.379

 −

5 (45.45%)

5 (41.67%)

 

18 (56.25%)

17 (56.67%)

 

5 (41.67%)

17 (56.67%)

 

PR, %

         

 + 

7 (63.64%)

8 (66.67%)

 > 0.999

13 (40.62%)

16 (53.33%)

0.316

8 (66.67%)

16 (53.33%)

0.43

 −

4 (36.36%)

4 (33.33%)

 

19 (59.38%)

14 (46.67%)

 

4 (33.33%)

14 (46.67%)

 

HER2, %

         

 + 

1 (9.09%)

0 (0.0%)

0.478

12 (37.50%)

9 (30.0%)

0.533

0 (0.0%)

9 (30.0%)

0.041

 −

10 (90.91%)

12 (100.0%)

 

20 (62.50%)

21 (70.0%)

 

12 (100.0%)

21 (70.0%)

 

Ki67, %

         

 < 14

1 (9.09%)

2 (16.67%)

 > 0.999

6 (18.75%)

4 (13.33%)

0.733

2 (16.67%)

4 (13.33%)

 > 0.999

 ≥ 14

10 (90.91%)

10 (83.33%)

 

26 (81.25%)

26 (86.67%)

 

10 (83.33%)

26 (86.67%)

 

Metastasis site, %

         

 ≤ 2

8 (72.73%)

11 (91.67%)

0.317

13 (40.62%)

19 (63.33%)

0.074

11 (91.67%)

19 (63.33%)

0.066

 > 2

3 (27.27%)

1 (8.33%)

 

19 (59.38%)

11 (36.67%)

 

1 (8.33%)

11 (36.67%)

 

Primary tumor excised, %

         

 Yes

8 (72.73%)

12 (100.0%)

0.093

23 (71.88%)

24 (80.0%)

0.455

12 (100.0%)

24 (80.0%)

0.094

 No

3 (27.27%)

0 (0.0%)

 

9 (28.12%)

6 (20.0%)

 

0 (0.0%)

6 (20.0%)

 

Received radiation therapy, %

         

 Yes

6 (54.55%)

7 (58.33%)

 > 0.999

14 (43.75%)

17 (56.67%)

0.309

7 (58.33%)

17 (56.67%)

0.921

 No

5 (45.45%)

5 (41.67%)

 

18 (56.25%)

13 (43.33%)

 

5 (41.67%)

13 (43.33%)

 

Received targeted therapy,%

         

 Yes

3 (27.27%)

0 (0.0%)

0.093

11 (34.38%)

5 (16.67%)

0.111

0 (0.0%)

5 (16.67%)

0.298

 No

8 (72.73%)

12 (100.0%)

 

21 (65.62%)

25 (83.33%)

 

12 (100.0%)

25 (83.33%)

 

Received endocrine therapy, %

         

 Yes

4 (36.36%)

7 (58.33%)

0.414

11 (34.38%)

13 (43.33%)

0.469

7 (58.33%)

13 (43.33%)

0.379

 No

7 (63.64%)

5 (41.67%)

 

21 (65.62%)

17 (56.67%)

 

5 (41.67%)

17 (56.67%)

 
  1. ER and PR status was defined with the cutoff value of 1% positive tumor cells. HER2-positive was defined as scored 3 + by immunohistochemistry; for scores 2 + , fluorescence in situ hybridization was performed to determine HER2 positivity; and 0 and 1 + were regarded as HER2-negative
  2. BMI: body mass index; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor type 2; UX (Utidelone plus Capecitabine); Eri (Eribulin)
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us